Cargando…
Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial
For almost three decades in many countries azathioprine has been used to treat relapsing-remitting multiple sclerosis. However its efficacy was usually considered marginal and following approval of β interferons for this indication it was no longer recommended as first line treatment, even if presen...
Autores principales: | Massacesi, Luca, Tramacere, Irene, Amoroso, Salvatore, Battaglia, Mario A., Benedetti, Maria Donata, Filippini, Graziella, La Mantia, Loredana, Repice, Anna, Solari, Alessandra, Tedeschi, Gioacchino, Milanese, Clara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234663/ https://www.ncbi.nlm.nih.gov/pubmed/25402490 http://dx.doi.org/10.1371/journal.pone.0113371 |
Ejemplares similares
-
Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis
por: Amoriello, Roberta, et al.
Publicado: (2022) -
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015) -
Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance
por: Mariottini, Alice, et al.
Publicado: (2022) -
Azathioprine Hypersensitivity Syndrome: Two Cases of Febrile Neutrophilic Dermatosis Induced by Azathioprine
por: Aleissa, Majed, et al.
Publicado: (2017) -
A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis—A Prospective Cohort Study
por: Agrawal, Arpit, et al.
Publicado: (2023)